2. UroToday Home
  3. Available Urotoday Newsletters - Site Registration Required

Prostate Cancer Weekly

Genomic Insights in Metastatic Hormone-Sensitive Prostate Cancer Sent on 29 November 2024
In Gratitude and Appreciation, A Message From UroToday!Sent on 27 November 2024
UroAlerts - Prostate Cancer WeeklySent on 26 November 2024
Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer TreatmentsSent on 25 November 2024
Emerging Technologies to Advance Urologic Care in 2025 - LUGPA 2024 Annual Meeting PresentationsSent on 23 November 2024
Integrating New Technologies into Practice Management: LUGPA 2024 Annual EducationSent on 22 November 2024
Precision Medicine at the Forefront of mCRPC TherapySent on 21 November 2024
Innovative Therapies in GU CancersSent on 20 November 2024
UroAlerts - Prostate Cancer WeeklySent on 19 November 2024
Variant Histology Bladder Cancer Challenges and Future DirectionsSent on 18 November 2024
Advances in Staging and Personalized Radiation TherapySent on 15 November 2024
Risk Assessment and Treatment Intensification in Advanced Prostate CancerSent on 14 November 2024
Reducing Financial Burdens and Advancing Personalized Prostate Cancer Care for VeteransSent on 13 November 2024
UroAlerts - Prostate Cancer WeeklySent on 12 November 2024
Breakthrough Data in the Treatment of Advanced Prostate Cancer Sent on 08 November 2024
Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global ImplementationSent on 07 November 2024
Targeted Treatment with Radioligand Therapy in Advanced Prostate CancerSent on 06 November 2024
UroAlerts - Prostate Cancer WeeklySent on 05 November 2024
Advanced Prostate Cancer - Understanding Out-of-Pocket Medication CostsSent on 05 November 2024
Machine Learning Predicts Financial Toxicity in Stage IIA Non-Seminoma TreatmentsSent on 04 November 2024
South Central Section American Urological Association (AUA): Insights in Prostate Cancer Treatment Sent on 31 October 2024
UroAlerts - Prostate Cancer WeeklySent on 29 October 2024
Strategies for Diagnosis and Treatment of Metastatic Prostate CancerSent on 25 October 2024
Evaluating Combination Treatments in Various Stages of Prostate Cancer Sent on 24 October 2024
UroAlerts - Prostate Cancer WeeklySent on 22 October 2024
Practice-Changing Prostate Cancer Clinical Trials Data - ARANOTE - PREACE-3 and SPLASH  Sent on 22 October 2024
Operationalizing and Patient Selection for Lutetium-177 PSMA TreatmentSent on 21 October 2024
Advancing mHSPC Care - Bridging Research and Clinical PracticeSent on 19 October 2024
Novel Targets Aim to Expand the Treatment Landscape of Metastatic Prostate Cancer Sent on 18 October 2024
UroAlerts - Prostate Cancer WeeklySent on 15 October 2024
Treatment Considerations in High-Risk Prostate Cancer Sent on 15 October 2024
Evidence-Informing Clinical Decision-Making in Metastatic Castration-Resistant Prostate CancerSent on 14 October 2024
The Roles of Molecular Imaging Towards Informing Clinical Treatment Decision Making in Prostate Cancer Sent on 11 October 2024
Advancing the Standard of Care in mHSPC Sent on 10 October 2024
UroAlerts - Prostate Cancer WeeklySent on 08 October 2024
Contemporary Treatment of Bone Metastatic Castration-Resistant Prostate Cancer Sent on 05 October 2024
ASTRO 2024 Featuring Validation of Digital Pathology MMAI Algorithm and of the Decipher® Genomic Testing in the VANDAAM Study Sent on 04 October 2024
ASTRO 2024 - The RAVENS - Outcomes of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerSSent on 03 October 2024
UroAlerts - Prostate Cancer WeeklySent on 01 October 2024
ASTRO 2024 Prostate Advanced Radiation Technologies Quality of Life (PARTIQoL)Sent on 01 October 2024
American Society for Radiation Oncology (ASTRO) 2024: Radiotherapy Innovations in GU MalignanciesSent on 30 September 2024
Treatment Strategies for High-Risk Biochemically Recurrent Prostate CancerSent on 28 September 2024
Managing Castrate-Resistant Prostate CancerSent on 27 September 2024
UroAlerts - Prostate Cancer WeeklySent on 24 September 2024
How to Personalize Therapy in mHSPCSent on 23 September 2024
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment and More on Prostate CancerSent on 19 September 2024
UroAlerts - Prostate Cancer WeeklySent on 17 September 2024
ESMO 2024 Practice Changing Prostate Cancer Trial Results Sent on 17 September 2024
ESMO 2024 Informing GU Cancer TreatmentsSent on 16 September 2024
ESMO 2024: SPLASH 177Lu-PNT2002 Improves Radiographic Progression-Free Survival in mCRPC Patients Sent on 15 September 2024
  • Page of 40
Display #
Results 1 - 50 out of 1978
Send the selected Newsletters to...